Edition:
India

TRACON Pharmaceuticals Inc (TCON.OQ)

TCON.OQ on NASDAQ Stock Exchange Global Market

2.10USD
2:29am IST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.10
Open
$2.10
Day's High
$2.12
Day's Low
$2.10
Volume
9,189
Avg. Vol
20,395
52-wk High
$4.65
52-wk Low
$2.00

Chart for

About

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company's research focuses on antibodies that bind to the endoglin receptor, which is... (more)

Overall

Beta: --
Market Cap(Mil.): $61.63
Shares Outstanding(Mil.): 16.66
Dividend: --
Yield (%): --

Financials

BRIEF-Ambrx And Tracon Pharma Announce Commercialization Agreement For TRC105 In China

* AMBRX AND TRACON PHARMACEUTICALS ANNOUNCE DEVELOPMENT AND COMMERCIALIZATION AGREEMENT FOR TRC105 IN CHINA

21 Dec 2017

BRIEF-Tracon Pharmaceuticals announces positive results from phase 1 trial of TRC102, Fludara

* Tracon Pharmaceuticals announces positive results from phase 1 trial of trc102 and fludara® in patients with advanced hematologic malignancy published in oncotarget

14 Nov 2017

BRIEF-Tracon Pharma reports third quarter financial results

* Tracon Pharmaceuticals reports third quarter financial results and provides corporate update

08 Nov 2017

BRIEF-683 Capital Management reports 5.4 pct passive stake in Tracon Pharmaceuticals

* 683 Capital Management Llc reports 5.4% passive stake in Tracon Pharmaceuticals Inc as of Sept 18, 2017 - SEC filing‍​ Source text: [http://bit.ly/2yb8Zbn] Further company coverage:

29 Sep 2017

BRIEF-Tracon Pharmaceuticals announces completion of enrollment in randomized phase 2B traxar study of TRC105 and Inlyta in renal cell carcinoma

* Tracon Pharmaceuticals announces completion of enrollment in randomized phase 2B Traxar study of TRC105 and Inlyta in renal cell carcinoma

07 Sep 2017

BRIEF-Tracon Pharmaceuticals files for offering of up to $14.33 mln of co's common stock‍​

* Files for offering of up to $14.33 million of co's common stock‍​ - SEC filing Source text for Eikon: Further company coverage:

05 Sep 2017

Earnings vs. Estimates